https://www.nasdaq.com/press-release/applied-therapeutics-provides-regulatory-update-on-galactosemia-program-2022-01-03
https://www.nasdaq.com/press-release/applied-therapeutics-announces-initiation-of-registrational-phase-2-3-study-of-at-007
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-14th-international-congress-of-inborn-errors
https://www.nasdaq.com/press-release/applied-therapeutics-reports-third-quarter-2021-financial-results-2021-11-12
https://www.nasdaq.com/press-release/applied-therapeutics-reports-biomarker-data-from-pilot-trial-of-at-007-in-sord
https://www.nasdaq.com/press-release/applied-therapeutics-reports-additional-pediatric-biomarker-data-from-action
https://www.nasdaq.com/press-release/applied-therapeutics-reports-initial-pediatric-biomarker-data-from-action
https://www.nasdaq.com/press-release/applied-therapeutics-reports-second-quarter-2021-financial-results-2021-08-12
https://www.nasdaq.com/press-release/applied-therapeutics-added-to-russell-microcapr-index-2021-06-28
https://www.nasdaq.com/press-release/applied-therapeutics-announces-presentation-of-data-on-the-prevalence-of-diabetic
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-on-diabetic-cardiomyopathy-and-prevalence-of-disease
https://www.nasdaq.com/press-release/applied-therapeutics-granted-fast-track-designation-by-fda-for-at-007-for
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-ubs-global-healthcare-virtual-conference-2021
https://www.nasdaq.com/press-release/applied-therapeutics-reports-first-quarter-2021-financial-results-2021-05-11
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease
https://www.nasdaq.com/press-release/applied-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-2021
https://www.nasdaq.com/press-release/applied-therapeutics-to-host-virtual-rare-disease-forum-2021-03-16
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-cowen-and-barclays-investor-conferences-2021
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-closing-of-public-offering-2021-02-22
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-pricing-of-public-offering-of-3000000-shares-of
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-offering-of-3000000-shares-of-common-stock-2021
https://www.nasdaq.com/press-release/applied-therapeutics-announces-restart-of-pediatric-galactosemia-study-2021-02-01
https://www.nasdaq.com/press-release/applied-therapeutics-to-be-added-to-nasdaq-biotechnology-index-2020-12-15
https://www.nasdaq.com/press-release/applied-therapeutics-announces-launch-of-galactosemia-awareness-and-education
https://www.nasdaq.com/press-release/applied-therapeutics-announces-mrs-data-from-action-galactosemia-study-2020-12-09
https://www.nasdaq.com/press-release/applied-therapeutics-reports-third-quarter-2020-financial-results-2020-11-12
https://www.nasdaq.com/press-release/applied-therapeutics-announces-presentation-of-pre-clinical-data-on-at-001-for-the
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-data-on-at-007-for-the-treatment-of-galactosemia-at
https://www.nasdaq.com/press-release/fda-grants-at-007-pediatric-rare-disease-designation-and-orphan-designation-for
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-data-on-at-001-for-treatment-of-diabetic
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-citi-and-baird-investor-conferences-2020-09-02
https://www.nasdaq.com/press-release/applied-therapeutics-reports-second-quarter-2020-financial-results-2020-08-11
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-data-on-at-007-for-treatment-of-galactosemia-at-the
https://www.nasdaq.com/press-release/applied-therapeutics-takes-action-against-fraudulent-short-report-2020-07-06
https://www.nasdaq.com/press-release/applied-therapeutics-announces-start-of-at-007-pediatric-galactosemia-study-releases
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-data-on-at-001-for-the-treatment-of-diabetic
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare
https://www.nasdaq.com/press-release/applied-therapeutics-announces-appointment-of-dr.-chuck-silberstein-md-mba-cfa-as
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-ubs-global-healthcare-conference-2020-05-12
https://www.nasdaq.com/press-release/applied-therapeutics-reports-first-quarter-2020-financial-results-2020-05-11
https://www.nasdaq.com/press-release/applied-therapeutics-announces-full-data-and-scientific-presentations-from-the
https://www.nasdaq.com/press-release/applied-therapeutics-announces-ind-and-investigator-initiated-studies-of-at-001-in
https://www.nasdaq.com/press-release/applied-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-2020
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-barclays-global-healthcare-conference-2020-03
https://www.nasdaq.com/press-release/applied-therapeutics-appoints-adam-hansard-as-chief-commercial-officer-2020-03-03
https://www.nasdaq.com/press-release/applied-therapeutics-to-present-at-the-cowen-and-company-40th-annual-health-care
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-closing-of-public-offering-and-exercise-in-full
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-upsizing-and-pricing-of-public-offering-of
https://www.nasdaq.com/press-release/applied-therapeutics-inc.-announces-offering-of-1750000-shares-of-common-stock-2020
https://www.nasdaq.com/press-release/applied-therapeutics-announces-positive-topline-results-of-pivotal-phase-2-action
https://www.nasdaq.com/press-release/applied-therapeutics-to-ring-nasdaq-closing-bell-on-december-17th-2019-12-16
https://www.nasdaq.com/press-release/applied-therapeutics-announces-presentation-of-pre-clinical-data-highlighting-at-001
https://www.nasdaq.com/press-release/applied-therapeutics-announces-presentations-outlining-the-design-and-rationale-for
https://www.nasdaq.com/press-release/applied-therapeutics-announces-presentation-of-clinical-data-highlighting-at-001-for
https://www.nasdaq.com/press-release/applied-therapeutics-reports-third-quarter-2019-financial-results-2019-11-13
